This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pozen Crushed by FDA Setback

Updated from 11:51 a.m. EDT

Pozen (POZN - Get Report), a drug-development firm with no commercial products, had nearly half of its market cap erased after U.S. regulators said they couldn't yet approve the company's proposed treatment for migraines.

The Food and Drug Administration issued what's called an approvable letter for Trexima, meaning certain conditions must be satisfied before the drug can be granted full marketing clearance.

Specifically, the FDA determined that Trexima is effective as an acute treatment for migraine headaches, but requested additional safety information. As a result, Trexima might require new studies.

Shares of Pozen plunged $6.87, or 49%, to $7.24 following the announcement. Trading volume was extremely heavy, with 6.7 million shares changing hands two hours into the day. That's more than 15 times the average for a full session.

Pozen, Chapel Hill, N.C., is developing Trexima with the U.K.'s GlaxoSmithKline (GSK - Get Report). The drug's developers plan to ask for a meeting with the FDA as quickly as possible to discuss the approvable letter and determine the next steps they should take.

Trexima combines the active ingredient in another migraine drug, Glaxo's Imitrex, and the painkiller naproxen sodium. Naproxen sodium is found in several brand-name prescription and over-the-counter medications, including Anaprox and Aleve.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
GSK $43.84 -3.14%
POZN $6.58 -1.94%
AAPL $129.62 -2.20%
FB $79.34 -1.50%
GOOG $532.32 -1.44%

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs